Published • loading... • Updated
NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials
NanoViricides will present at the NIBA 153rd Investment Conference, highlighting its broad-spectrum antiviral NV-387, which is in Phase 2 trials for Ebola and Mpox and has FDA designations for measles. The post NanoViricides to Present at NIBA Conference as NV-387 Advances in Ebola and Mpox Trials appeared first on citybuzz.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
